Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus QVAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus QVAR 80.
FLUTICASONE PROPIONATE vs QVAR 80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; binds to cytosolic glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins, leukotrienes) and suppression of immune cell activity.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
Inhalation: 88-440 mcg twice daily for asthma (DPI: 100-500 mcg twice daily; HFA: 44-220 mcg twice daily). Intranasal: 2 sprays (50 mcg/spray) per nostril once daily (total 200 mcg/day). Topical: Apply thin layer to affected area 1-2 times daily.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
None Documented
None Documented
Clinical Note
moderateFluticasone propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin."
Clinical Note
moderateFluticasone propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin."
Clinical Note
moderateFluticasone propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 7.8 hours after intravenous administration; extends to 10-14 hours following intranasal or inhaled routes due to slow absorption from the lung/nasal mucosa.
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
Primarily hepatic metabolism via CYP3A4 to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal elimination accounts for >90% of metabolites.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Fluticasone propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin."